• French Patent Litigators
  • The Firm
    • Know-how
    • Team
      • Matthieu DHENNE
      • Benjamin MOLLET-VIEVILLE
  • Fields of expertise
    • Patents
    • Employee Inventions
    • Contracts
    • Trade Secrets
    • Saisie-contrefaçon
    • Pharmaceutical regulations
    • UPC
  • Blog
  • Contact
  • French
  • French Patent Litigators
  • The Firm
    • Know-how
    • Team
      • Matthieu DHENNE
      • Benjamin MOLLET-VIEVILLE
  • Fields of expertise
    • Patents
    • Employee Inventions
    • Contracts
    • Trade Secrets
    • Saisie-contrefaçon
    • Pharmaceutical regulations
    • UPC
  • Blog
  • Contact
  • French

“AVELUMAB SPC Case”: A key U-turn in French case law

•Dhenne Avocats
•Uncategorized

25 May 2022, the Paris Court of Appeal overturned the refusal of the French National Institute of Industrial Property (INPI) to grant an SPC on avelumab. This is a reversal of the “nivolumab” case law on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 (SPC Regulation).

For more information: link.

Previous PostA preliminary injunction can be based on a patent application (“fingolimod case”)Next PostFrench Judge Competent for Infringement Abroad: Private International Law vs. UPC?

Related Posts

Trastuzumab x recombinant human hyaluronidase: the French Supreme Court clarifies the interpretation of article 1 b) of the SPC Regulation

•21 February 2023•Dhenne Avocats

“Nivolumab and pembrolizumab cases”: the French Supreme Court clarifies the interpretation of Article 3 a) of the SPC Regulation

•13 February 2023•Dhenne Avocats

“Thales” and “Bull” decisions: the French Supreme Court and the patentability of computer-implemented inventions

•7 February 2023•Dhenne Avocats